Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.048 AUD | +4.35% | +23.08% | +118.18% |
09/04 | Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial | MT |
28/02 | Anatara Lifesciences Ltd Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Sales 2022 | - | Sales 2023 | - | Capitalization | 3.36M 2.19M 183M |
---|---|---|---|---|---|
Net income 2022 | -2M -1.31M -109M | Net income 2023 | -2M -1.31M -109M | EV / Sales 2022 | - |
Net cash position 2022 | 1.1M 721K 60.15M | Net cash position 2023 | 401K 262K 21.85M | EV / Sales 2023 | - |
P/E ratio 2022 |
-1.54
x | P/E ratio 2023 |
-1.35
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 63.89% |
1 day | +4.35% | ||
1 week | +23.08% | ||
Current month | +23.08% | ||
1 month | +11.63% | ||
3 months | +92.00% | ||
6 months | +45.45% | ||
Current year | +118.18% |
Managers | Title | Age | Since |
---|---|---|---|
David Brookes
CEO | Chief Executive Officer | 63 | 23/19/23 |
John Michailidis
COO | Chief Operating Officer | - | - |
Simon Erskine
PRN | Corporate Officer/Principal | - | 06/21/06 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Brookes
CEO | Chief Executive Officer | 63 | 23/19/23 |
John Michailidis
COO | Chief Operating Officer | - | - |
Nicholas Haslam
BRD | Director/Board Member | - | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 0.048 | +4.35% | 506,975 |
24/24/24 | 0.046 | +6.98% | 111,942 |
23/24/23 | 0.043 | +2.38% | 22,046 |
22/24/22 | 0.042 | +7.69% | 1,130,501 |
19/24/19 | 0.039 | -7.14% | 510,000 |
Delayed Quote Australian S.E., April 26, 2024 at 11:40 am IST
More quotes1st Jan change | Capi. | |
---|---|---|
+118.18% | 5.26M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- ANR Stock